IDEAYA Biosciences IDYA 深 沪
等待开盘 08-20 09:30:00 美东时间
24.05
-0.700
-2.83%
华盛通- 最 高24.67
- 今 开24.45
- 成交量 105.88万股
- 最 低 23.915
- 昨 收 24.75
- 总市值 21.06亿
- 52周最高 40.25
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 13.45
- 委 比 -29.85%
- 总股本 8758.20万
- 历史最高 47.735
- 量 比 1.19
- 振 幅 3.05%
- 历史最低 2.95
- 每 手 1
- 风险率 6.02%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多IDEAYA Biosciences Announces Agenda for 10-Year Anniversary R&D Day on September 8, 2025
SOUTH SAN FRANCISCO, Calif., Aug. 18, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of target...
08-18 18:00
Ideaya Biosciences Advances in Ocular Melanoma Treatment with Darovasertib Study
Ideaya Biosciences (($IDYA)) announced an update on their ongoing clinical stud...
08-05 00:06
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Aug. 1, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targete...
08-01 18:00
【天风医药杨松团队|公司专题研究】泽璟制药：兼具销售放量和研发成果兑现的优秀创新药企
（来源：一棵大松树） 已实现三个重点品种商业化，重组人促甲状腺激素有望于近期上市 截至2025年5月，公司已成功实现3款重点药物上市销售...
08-01 16:01
JP Morgan Maintains Overweight on IDEAYA Biosciences, Raises Price Target to $72
JP Morgan analyst Anupam Rama maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Overweight and raises the price target from $66 to $72.
07-28 19:56
最高120亿美元！恒瑞官宣与GSK最多12项授权交易，慢阻肺药成下个热门？
港股上市两个月后，恒瑞医药官宣了一笔“打包式”BD（商务拓展），首付款5亿美元。 7月28日，恒瑞医药（600276.SH；1276.HK）公告称，公司与葛兰素...
07-28 11:19
TD Cowen Initiates Coverage On IDEAYA Biosciences with Buy Rating
TD Cowen analyst Tyler Van Buren initiates coverage on IDEAYA Biosciences (NASDAQ:IDYA) with a Buy rating.
07-22 20:04
IDEAYA Biosciences to Participate in Upcoming July 2025 Investor Relations Event
SOUTH SAN FRANCISCO, Calif., July 21, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of target...
07-21 18:00
RBC Capital Maintains Outperform on IDEAYA Biosciences, Lowers Price Target to $30
RBC Capital analyst Leonid Timashev maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and lowers the price target from $57 to $30.
07-09 20:48
